1.	Phase III Randomized Study of Chemoimmunotherapy Comprising Gemcitabine Hydrochloride and Capecitabine With or Without Telomerase Peptide Vaccine GV1001 in Patients With Locally Advanced or Metastatic Pancreatic Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: CRUK-TELOVAC-V4, EUDRACT-2006-000461-10, EU-20683, ISRTCN43482138, NCT00425360, TELOVAC
2.	Immunotherapy Study for Surgically Resected Pancreatic Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NLG0405, OBA# 0912-1013, NCT01072981
3.	Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 19 to 90 Sponsor: Other Protocol IDs: SuMo-Sec-01, PEI 0899/01, IRB 07/03, NCT00108875
4.	A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J09100, NA_00031401, NCT01088789
5.	Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: NCI Protocol IDs: NCI-2012-03111, 070602, U01CA132194, CINJ-070602, 7606, CINJ-IRB-0220060270, NCT00669734
6.	Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 10105, NCI-2010-01859, NCT01191684
7.	VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VXM01-01-DE, NCT01486329
8.	Phase 1 Study of ONT-10 in Patients With Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: ONT-10-001, NCT01556789
9.	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: JHOC-J0810, CDR0000600355, P30CA006973, JHOC-J0810, JHOC_NA_00015858, J0810, NCT00727441
10.	Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas Phase: No phase specified Type: Treatment Status: Active Age: 18 to 76 Sponsor: Other Protocol IDs: J1179, NA_00050233, NCT01595321
11.	A Study of Vaccination With Poly-ICLC and Dendritic Cells in HLA-A2 Negative Patients With Pancreatic Adenocarcinoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 101778, NCT01677962